Sign in

    Matthew Aspro

    Research Analyst at Jefferies

    Matthew Aspro is an Equity Associate at Jefferies LLC specializing in equity research, with recent coverage including companies such as Allurion Technologies in the medical supplies and devices sector. Since joining Jefferies in 2024, Aspro has contributed to investment analysis and research, leveraging previous experience as an Analyst at Davis-Rea Ltd. from 2021 to 2024 and other roles in investment analysis, equity derivatives sales, and treasury markets. He holds FINRA registration as a broker with Jefferies and has a background indicative of relevant securities licensing. Aspro's analytical work supports key investment decisions and client communications within the firm.

    Matthew Aspro's questions to STRYKER (SYK) leadership

    Matthew Aspro's questions to STRYKER (SYK) leadership • Q2 2025

    Question

    Matthew Aspro of Jefferies asked about the implications of the recent OB VBA bill on hospital purchasing behavior and the outlook for Stryker's tax rate into 2026.

    Answer

    VP of Finance & IR Jason Beach stated that Stryker is monitoring the bill but sees minimal impact as Medicaid is a small part of its procedure base and capital demand remains tied to strong procedure volumes. VP & CFO Preston Wells noted that while the bill may provide a cash tax benefit, he does not expect a significant impact on the company's effective tax rate (ETR), which should remain in a similar range to the current 15-16% guide.

    Ask Fintool Equity Research AI